Technology
Health
Biotechnology

Jounce Therapeutics

$6.87
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.24 (3.64%) Today
+$0.03 (0.44%) After Hours

Why Robinhood?

You can buy or sell JNCE and other stocks, options, ETFs, and crypto commission-free!

About

Jounce Therapeutics, Inc. Common Stock, also called Jounce Therapeutics, is a clinical stage immunotherapy company, which treat cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients. Read More Its products pipeline include JTX-2011 (ICOS); JTX-4014 (PD-1); Lead Macrophage Program; Macrophage Targeting; T Reg; B Cells; and Stromal Targeting. The company was founded by Louis M. Weiner, Drew M. Pardoll, Thomas F. Gajewski, James P. Allison, Robert Schreiber and Padmanee Sharma in 2013 and is headquartered in Cambridge, MA.

Employees
115
Headquarters
Cambridge, Massachusetts
Founded
2013
Market Cap
217.41M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
428.36K
High Today
$7.00
Low Today
$6.36
Open Price
$6.59
Volume
130.70K
52 Week High
$27.24
52 Week Low
$2.66

Collections

Technology
Health
Biotechnology
Therapy
Medical
2017 IPO
US
North America

News

Associated PressMar 6

Jounce Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results

- New data from two programs to be presented at AACR - - New Phase 2 studies to be initiated in 2019 supported by established safety from dose escalation cohorts of vopratelimab (JTX-2011), with ipilimumab and with pembrolizumab - - Ended 2018 with $195.9 million in cash, cash equivalents and investments - - Company to host conference call and webcast today at 8:00 AM ET - CAMBRIDGE, Mass., March 06, 2019 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on t...

176
Markets InsiderFeb 27

Jounce Therapeutics to Present Data from its JTX-2011 and JTX-8064 Programs at the 2019 American Association for Cancer Research (AACR) Annual Meeting

ICONIC Clinical Data Demonstrates Improved PFS/OS in Patients with Emergence of JTX-2011 Mechanistic Biomarker (ICOS high CD4 T cells) Company to Host Investor Event and Live Webcast on Tuesday, April 2, 2019 CAMBRIDGE, Mass., Feb. 27, 2019 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that data from its Phase 1/2 ICONIC trial, an open label trial e...

166

Earnings

-$0.49
-$0.35
-$0.20
-$0.06
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.36 per share
Actual
-$0.06 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.